Medical Condition News

RSS

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011

Tips for preventing outdoor home-related injury: AANS

The nail-gun neck injury and treatment incurred by a 25-year-old carpenter described in the Journal of Neurosurgery: Spine article might read like an oddity, but nail guns are actually a common form of penetrating low-velocity injury. What made this case unique was that the patient incurred a penetrating wound to the cervical spine by a barbed nail lodged in close proximity to the right vertebral artery.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

What starts as burning, numbness, pain, and/or tingling in the feet, or hands in some can turn into a debilitating condition. Peripheral Neuropathy (PN), one of the largest and most common neurodegenerative disorders, affects more than 20 million Americans of all races and ethnic backgrounds.

9 Jun 2011

Ameritox launches Rx Guardian CD, next-generation pain-medication monitoring solution

Ameritox, the leader in pain-medication monitoring, today announced the launch of Rx Guardian CD, its next-generation pain-medication monitoring solution and part of the patented Rx Guardian process.

9 Jun 2011

Adaptive optics technology reveals eye's cellular structure with unprecedented detail

Scientists today reported that the tiny light-sensing cells known as rods have been clearly and directly imaged in the living eye for the first time. Using adaptive optics (AO), the same technology astronomers use to study distant stars and galaxies, scientists can see through the murky distortion of the outer eye, revealing the eye's cellular structure with unprecedented detail.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

Adults with herpes zoster may face higher risk of multiple sclerosis

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

The American Society of Clinical Oncology (ASCO) on Monday sent a letter signed by major U.S. medical societies representing about 300,000 health care professionals to the White House urging President Barack Obama to participate in the U.N. High Level Meeting on Noncommunicable Diseases that is scheduled for September, Agence France-Presse reports.

9 Jun 2011

New NCIN report: Poorer women more likely to die from breast cancer

Poorer women from deprived areas are less likely to survive breast cancer as they are diagnosed at a later stage which means the best available treatments won't be as effective according to a new report out today (Thursday) by the National Cancer Intelligence Network (NCIN).

9 Jun 2011

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

RegeneRx Biopharmaceuticals, Inc. has announced that thymosin beta 4 (Tβ4) can activate a unique subpopulation of resident adult epicardial stem cells such that they recapture embryonic potential, proliferate, migrate and differentiate into functional heart muscle (cardiomyocytes), according to a research paper published online today in Nature.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Older people who engage in moderate to intense exercise less likely to have silent strokes

Older people who regularly exercise at a moderate to intense level may be less likely to develop the small brain lesions, sometimes referred to as "silent strokes," that are the first sign of cerebrovascular disease, according to a new study published in the June 8, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Medical Condition News

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Synaptophysin controls replacement of vesicles

Tips for preventing outdoor home-related injury: AANS

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

Ameritox launches Rx Guardian CD, next-generation pain-medication monitoring solution

Adaptive optics technology reveals eye's cellular structure with unprecedented detail

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Adults with herpes zoster may face higher risk of multiple sclerosis

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

New NCIN report: Poorer women more likely to die from breast cancer

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Older people who engage in moderate to intense exercise less likely to have silent strokes

Article reports on bright future and enormous need for stem cell therapeutics

Patient enrollment complete in cilengitide Phase III study against glioblastoma

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News